On October 16, 2023 Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, reported that updated data from its Phase 1/2 SPENCER study on EO2401 in combination with nivolumab, in patients with adrenal tumors, will be presented in an oral session at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2023, to take place on October 20-23, 2023 in Madrid, Spain (Press release, Enterome, OCT 16, 2023, View Source [SID1234635996]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral Presentation details – Abstract 724O
Title: EO2401 (E) peptide immunotherapy + nivolumab (N) in adrenocortical carcinoma (ACC) and metastatic pheochromocytoma/paraganglioma (MPP); EOADR1-19/SPENCER
Presenter: Dr. Eric Baudin, Associate Professor and Head of the Endocrine Oncology Unit at Gustave Roussy (Villejuif, France)
Session Title: Proffered Paper Session – NETs and endocrine tumors
Presentation Date and Time: Sunday, October 22, 2023, at 9.30 am CET
Location: Toledo Auditorium – Hall 3
The abstract was published today and is available online in the ESMO (Free ESMO Whitepaper) Congress 2023 Abstract Book (a supplement to the official ESMO (Free ESMO Whitepaper) journal, Annals of Oncology).
About SPENCER
SPENCER (EOADR1-19) is a multicenter, open-label, first-in-human, Phase 1/2 study of EO2401 in combination with an immune checkpoint inhibitor (nivolumab) for the treatment of patients with locally advanced or metastatic adrenocortical carcinoma (ACC), or malignant pheochromocytoma/paraganglioma (MPP). The study aims to assess the safety, tolerability, immunogenicity, and preliminary efficacy of the combination at sites in Europe and the US.
For more information on the Phase 1/2 trial of EO2401 in adrenal tumors, please refer to ClinicalTrials.gov Identifier: NCT04187404
About EO2401
EO2401 is Enterome’s first-in-class off-the-shelf OncoMimics peptide-based immunotherapy. It combines three microbial-derived OncoMimics peptides that closely mimic specific cytotoxic T cell (CD8+ T cell) epitopes on the Tumor-Associated Antigens IL13Ra2, BIRC5, and FOXM1, combined with the helper peptide (CD4+ T cell epitope) Universal Cancer Peptide 2 (UCP2).
About OncoMimics
OncoMimics immunotherapies are designed to activate pre-existing effector memory T cells that target bacterial (non-self) peptides, which are strongly cross-reactive against selected Tumor-Associated Antigens (TAAs), or B cell markers expressed on tumoral cells, resulting in a rapid, targeted cytotoxic response against cancer.